Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping Technology
July 21 2021 - 7:07AM
Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop
synthetic biology systems, today announced a licensing and supply
agreement with TriLink Biotechnologies, part of Maravai
LifeSciences (NASDAQ: MRVI), for its industry-leading CleanCap®
technology. Codex DNA will integrate the mRNA capping technology
into its suite of automated mRNA synthesis kits for the BioXp™
system as well as within the company’s BioFoundry Services
offering. Together, the technologies are expected to increase
productivity and yields for mRNA synthesis workflows, potentially
opening the doors for a broader range of downstream therapeutic and
vaccine applications.
Therapeutics and vaccines have become increasingly dependent on
mRNA. However, the manual, multi-step process required to build
mRNA is tedious and often fraught with technical difficulties and
bottlenecks that require long turnaround times.
Codex DNA’s new BioXp small-scale mRNA synthesis kit with
CleanCap reagents is expected to overcome many of these challenges
by increasing the yields and productivity of synthetically designed
mRNA products. Customers will now have the option to generate up to
16 biologically active mRNA constructs at a yield of at least 10
micrograms each from fully de novo synthesized and error-corrected
genes in a single automated run. These combined technologies
increase the fraction of translationally active mRNA during
transcription, which simplifies and shortens the mRNA manufacturing
process and results in higher levels of protein production.
“We are passionate about improving the quality and output of
mRNA synthesis workflow, and excited to collaborate with the
synthesis pioneers at Codex DNA to bring CleanCap technology to a
broader audience,” said Jeff Whitmore, Vice President Commercial
Operations at TriLink Biotechnologies. “We believe our combined
technologies will help users move therapeutic candidates more
quickly from preclinical to clinical production stages.”
“The TriLink CleanCap technology is the current industry
standard for capping mRNA and this collaboration enables us to
expand the range of applications for our award-winning BioXp
system,” said Todd R. Nelson, PhD, CEO of Codex DNA. “Our customers
will be able to take advantage of significant time and cost savings
during the design-build-test phases for identifying mRNA-based
vaccine and therapeutic candidates.”
About TriLink BioTechnologies
TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO
helping life science leaders and innovators overcome challenges in
the synthesis and scale-up of nucleic acids, NTPs and mRNA capping
analogs with scale-up expertise and unique mRNA production
capabilities, including its proprietary CleanCap® mRNA capping
technology. TriLink continues to expand its cGMP and general
manufacturing capacity at its new global headquarters to support
mRNA, oligonucleotide & plasmid therapeutic, vaccine and
diagnostic customers. www.trilinkbiotech.com
About Maravai LifeSciencesMaravai is a leading
life sciences company providing critical products to enable the
development of drug therapies, diagnostics, novel vaccines and
support research on human diseases. Maravai's companies are leaders
in providing products and services in the fields of nucleic acid
synthesis, bioprocess impurity detection and analysis, and protein
labeling and detection to many of the world's leading
biopharmaceutical, vaccine, diagnostics, and cell and gene therapy
companies.For more information about Maravai LifeSciences,
visit www.maravai.com.
About Codex DNA
Codex DNA is a synthetic biology company focused on enabling
researchers to rapidly, accurately and reproducibly build or
“write” high-quality synthetic DNA and mRNA that is ready to use in
many downstream synthetic biology enabled markets. Codex DNA’s
synthetic biology solution addresses the bottlenecks across the
multi-step process of building DNA and mRNA, as well as the
significant limitations of existing solutions that prevent the
rapid building of virtually error-free DNA and mRNA at a useable
scale. A key part of Codex DNA’s solution is the BioXp™ system, an
end-to-end automated workstation that fits on the benchtop and is
broadly accessible due to its ease-of-use and hands-free
automation. Codex DNA believes the BioXp™ system can democratize
synthetic biology by simplifying the process of building DNA and
mRNA, thereby accelerating the discovery, development, and
production of novel high-value products, including antibody-based
biologics, mRNA-based vaccines and therapeutics and precision
medicines.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on
Codex DNA’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Codex DNA’s actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. These
statements include but are not limited to statements regarding
Codex DNA’s ability to successfully integrate the CleanCap
technology into its products or the combined solution’s ability to
increase productivity and yields. These and other risks are
described more fully in Codex DNA’s filings with the Securities and
Exchange Commission (“SEC”) and other documents that Codex DNA
subsequently files with the SEC from time to time. Except to the
extent required by law, Codex DNA undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
Codex DNA, the Codex DNA logo, Gibson Assembly, and BioXp are
trademarks of Codex DNA Inc.
Contact:
Jennifer McNealey
Chief Financial Officer
ir@codexdna.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024